FDA trial clearance doesn't mean age reversal is coming by 2030?

checkthis · automated fact-check · How we check · Reel by @hey_ismaeel

The Reel accurately cites longevity milestones but misleads by framing an early Phase 1 trial for eye disease as proof of public age reversal by 2030. While the FDA cleared Life Biosciences for a human clinical trial of partial epigenetic reprogramming (ER-100), it is a Phase 1 safety study strictly for patients with specific eye diseases like glaucoma. Sam Altman did invest $180 million in Retro Biosciences and Sinclair's lab achieved cell rejuvenation in mice, as reported by Nature Biotechnology and MIT Technology Review. However, early safety trials for vision loss do not translate to widespread age reversal for the general public by 2030.

4 claims checked
4 sources
Checked 9 Nov 2026
Main source: Sam Altman invested $180 million into a company trying to delay death | MIT Technology Review

▶

The Reel we checked

@hey_ismaeel

Your only job is to not die before 2030. OpenAI’s Sam Altman put $180M into a company trying to add 10 healthy years to human life. The people building AI are…

Watch on Instagram ↗

Red flags

Accounts don't match

David Sinclair's research claims regarding age reversal have faced scientific debate and criticism regarding peer-review speed and methodology.

“David Sinclair’s latest study, published in a journal for which he is co-editor-in-chief, rocketed through the peer-review process more rapidly than usual.” David Sinclair's Age Reversal Study Claims Spark Controversy and Debate | NAD, 2023-07-25

What we checked

OpenAI's Sam Altman invested $180 million into a company working to add 10 healthy years to human life.“Altman cut checks totaling $180 million the same year.”Sam Altman invested $180 million into a company trying to delay death | MIT Technology Review

David Sinclair stated that his lab reversed biological aging by 75% in six weeks in animal models.“This Scientist Reversed Aging by 75% | David Sinclair - World Governments Summit”This Scientist Reversed Aging by 75% | David Sinclair - World Governments Summit - YouTube

David Sinclair stated that his lab cured blindness in animals for the first time using epigenetic reprogramming.“the researchers successfully reversed vision loss in animals with a condition mimicking human glaucoma, a leading cause of blindness around the world.”Vision Revision | Harvard Medical School

The US FDA cleared human clinical trials for epigenetic reprogramming therapy aimed at age reversal.“Life Biosciences received clearance from the US Food and Drug Administration for a phase 1 trial to test their partial epigenetic reprogramming approach in people with eye disease.”FDA go-ahead to test cellular rejuvenation therapy in humans | Nature Biotechnology

What the Reel doesn't tell you

The FDA clearance is for an early Phase 1 safety trial evaluating patients with specific eye diseases (glaucoma and NAION), not an approval or trial for broad commercial age reversal in healthy individuals by 2030.
David Sinclair stated at the World Governments Summit that epigenetic reprogramming can reverse cellular aging and restored vision in animal models (World Governments Summit).
Life Biosciences announced that FDA clearance of its IND application for ER-100 is the first partial epigenetic reprogramming therapy to reach human clinical trials (Life Biosciences).

Short version

⚠️ MISLEADING 👉 FDA clearance for an early eye disease trial does not mean public age reversal will be available by 2030. 👉 The FDA cleared Life Biosciences for a Phase 1 safety study strictly for patients with specific eye diseases like glaucoma. 🔎 Full check: send this Reel to @checkthis.chat